Clinical Trials Directory

Trials / Unknown

UnknownNCT03766919

Safety and Electrical Performance Evaluation of INVICTA Leads Models Equipped With DF4 Connector

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
33 (actual)
Sponsor
MicroPort CRM · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to assess the safety and key electrical performance of the INVICTA leads equipped with DF4 connector: ACTIVE fixation type models (single and dual coil: INVICTA 1CR, INVICTA 2CR) and PASSIVE fixation type models (single and dual coil: INVICTA 1CT, INVICTA 2CT).

Detailed description

FRIENDS study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study. The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D). This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR) and passive fixation, either single coil (model 1CT) or dual coil (model 2CT) leads models. The clinical data will be used to support the application to CE marking of INVICTA leads. The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. A maximum number of 224 patients will be enrolled in the study, in up to 60 centers in Europe. The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant .

Conditions

Interventions

TypeNameDescription
DEVICEImplant of the INVICTA leadThe implant or the attempt to implant an INVICTA lead

Timeline

Start date
2018-12-27
Primary completion
2020-03-01
Completion
2021-03-01
First posted
2018-12-06
Last updated
2019-04-16

Locations

10 sites across 4 countries: France, Italy, Portugal, Spain

Source: ClinicalTrials.gov record NCT03766919. Inclusion in this directory is not an endorsement.